EyePoint CMO exercises options, sells 2,438 shares

EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported insider transactions involving stock options and common shares.

Rhea-AI Filing Summary

EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported insider transactions involving stock options and common shares. On March 4, 2026, he exercised a stock option covering 2,438 shares of common stock at an exercise price of $8.2600 per share and reported acquiring the corresponding common shares. He then sold 2,438 shares of common stock in open-market transactions at a weighted average price of $17.8719 per share, with individual sale prices ranging from $17.22 to $18.45. A separate option grant is disclosed as vesting 25% on January 3, 2026, with the remainder vesting monthly over the following three years.

Insider Trade Summary

Exercise and Sale: 2,438 shares ($23K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Ribeiro Ramiro

Role Chief Medical Officer

Sold 2,438 shs ($44K)

Approx. gross sale proceeds $44K

Approx. exercise cost $20K

Approx. pre-tax spread $23K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,438	$0.00	$0.00
Exercise	Common Stock	2,438	$8.26	$20K
Sale	Common Stock	2,438	$17.8719	$44K

Holdings After Transaction: Stock Option (Right to Buy) — 82,875 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.22 to $18.45. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

FAQ

What insider transactions did EyePoint (EYPT) report for Ramiro Ribeiro?

EyePoint’s Chief Medical Officer, Ramiro Ribeiro, exercised options for 2,438 common shares at an exercise price of $8.2600 per share and reported selling 2,438 common shares in open-market transactions at a weighted average price of $17.8719 per share on March 4, 2026.

At what prices were Ramiro Ribeiro’s EyePoint (EYPT) shares sold?

The reported 2,438 EyePoint common shares were sold at a weighted average price of $17.8719 per share. According to the disclosure, individual sale transactions occurred at prices ranging from $17.22 to $18.45 per share, all on March 4, 2026.

How many EyePoint (EYPT) shares were involved in Ramiro Ribeiro’s option exercise?

The option exercise covered 2,438 shares of EyePoint common stock. These shares were acquired at an exercise price of $8.2600 per share as reported, and the related transactions were dated March 4, 2026, in the Form 4 filing for the Chief Medical Officer.

What vesting schedule applies to Ramiro Ribeiro’s EyePoint (EYPT) stock option?

The disclosed option will vest and become exercisable 25% on January 3, 2026. The remaining 75% will then vest ratably on a monthly basis over the following three years, according to the vesting schedule described in the footnote to the insider transaction.

How is the weighted average sale price explained in EyePoint (EYPT) CMO’s filing?

The filing states the reported $17.8719 sale price is a weighted average. The 2,438 shares were sold in multiple transactions at prices between $17.22 and $18.45, and full price-by-lot details are available from EyePoint, its security holders, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ribeiro Ramiro

(Last) (First) (Middle)

C/O EYEPOINT, INC

480 PLEASANT STREET, SUITE C400

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EyePoint, Inc. [ EYPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		2,438	A	$8.26	2,438	D
Common Stock	03/04/2026		S		2,438	D	$17.8719(1)	0.00	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.26	03/04/2026		M			2,438	(2)	01/03/2035	Common Stock	2,438	$0.00	82,875	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.22 to $18.45. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

Remarks:

	/s/ Ron Honig, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.